Syntara’s Post

🚨 Acticor Biotech: Strategic Appointment and Clinical Developments! 🚨   We are sharing two major updates for Acticor Biotech :  🔹 Clinical Focus: Acticor Biotech is preparing the design for an upcoming GLORIA clinical trial, aimed at assessing glenzocimab's benefits in angioplasty for STEMI. Currently, 27 patients have been enrolled in the Phase 2b LIBERATE study, evaluating our innovative drug, glenzocimab, in the treatment of ST-Elevation Myocardial Infarction (STEMI).  🔗 : https://lnkd.in/edRtDvhX 🔹 Francois Guillet has been appointed as Chief Financial Officer. With his extensive experience in restructuring and international management, François will be a valuable asset in guiding Acticor Biotech through this strategic phase. We are thankful to Eric COHEN for his remarkable contributions since 2016, especially during Acticor's IPO. 🔗 : https://lnkd.in/ej3Y4Ukc #Biotech #innovation #clinicaldevelopment

Thoughts on this? >> Scholar Rock aims to raise $275M; Vincerx to reshuffle pipeline focus >> Comment below! >>> lqventures.com #pharma #healthcare #biotech #pharmaceutical #productmarketing

A new total-body PET scanner that is quicker for the patient and produces higher quality images for faster and earlier diagnosis andtreatmentof illnesses like cancer and heart conditions, was unveiled by Ministers in London yesterday (Wednesday 27 November). The new scanner, one of three becoming operational in the UK, is up to 40 times more sensitive and up to 10 times faster than existing machines, meaning quicker diagnoses and a more detailed reading of the patient's whol... https://bit.ly/3CW4yDS #pharma #biotech #lifesciences #clinicalresearch #news #pharmiweb

Humbled to see our paper published on biologics in elderly #asthmatics . Very Proud of our resident, HyeIn Ji, for her leadership in this project! Link to the paper: https://lnkd.in/gJQtN_Ux Loma Linda University Laren Tan, MD, MBA #RespiratoryCare #Asthma #respiratory #pulmonarymedicine #pulmonary

Financing led by OrbiMed, Avoro Capital, and Samsara BioCapital, with additional investment from founding investor Medicxi Strengthens its leadership team with the appointments of industry veterans Rick Anderson as SVP Finance, Spencer Fisk as Chief Technical and Quality Officer, and Ling Zeng as General Counsel and EVP of Execution IND-enabling studies underway for first-in-class PD1/VEGFR2 bifunctional antibody [19 December 2024]: [London, UK/ Boston, US]: Ottimo Pharma (“Ottimo”), a priv... https://bit.ly/400Y7Zd #pharma #biotech #lifesciences #clinicalresearch #news #pharmiweb

Excited to see Ab Studio’s first outlicensed Fc+ TCE asset, GB261 got a new deal by the licensee (Genorbio): https://lnkd.in/gis8nSSa Happy to see the first baby from our patent granted Fc+ TCE platform will move forward to autoimmune disease field. Since the world’s first Fc+ TCE, Catumaxomab, showed dose dependent hepatotoxicity in patients with EPCAM-positive cancers and one patient died from acute liver failure after receiving 10ug of catumaxomab, almost all major players in the TCE field either removed or silenced Fc effector function. GB261 is the world’s second Fc+ TCE entered into clinical trials and the world’s first Fc+ TCE showed great safety, efficacy balance in human at as high as 300mg dosage. The clinical POC data suggested that Ab Studio’s computer aided design platform could resolve challenges that traditional technologies can not. We hope our platforms, technologies and new assets to be outlicensed continue to support more partners!

🔥 𝗗𝗲𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗪𝗲𝗲𝗸 🔥 #49: miDiagnostics Raises €30M in Series D Funding miDiagnostics, a Leuven, Belgium-based qPCR technology company focused on delivering diagnostic tests directly to patients and clinicians, has secured €30 million in Series D funding. The funding round was led by Thermo Fisher Scientific Inc. (NYSE: TMO), with additional backing from Alychlo, VMF Invest, and Pamica. The investment will be used to advance the development of a sterility test for batch release, along with other quality control tests for the BioPharma industry, leveraging the company’s proprietary qPCR technology. 👏 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘵𝘩𝘦 𝘦𝘯𝘵𝘪𝘳𝘦 𝘵𝘦𝘢𝘮! News Link ➡️ https://lnkd.in/g9bP6z7f Katleen Verleysen Vesna Kostanjevecki Ben Chambers Els Degroote José Luis Morales Hellín Jacopo Binati Makar Vergovskiy Iman Saïd Philipp Sakuler

🔔 We are delighted to welcome metaLead Therapeutics AG to the BaseLaunch portfolio!     A spin-out from the University of Zurich, metaLead is advancing therapies for metal-related diseases, with a focus on Wilson disease, a rare condition caused by toxic copper buildup.     Founded by Dr. Michal Shoshan (CEO), an expert in inorganic medicinal chemistry, the company leverages its innovative drug development platform to pioneer treatments for unmet medical needs.     We look forward to supporting the metaLead team as they advance their pipeline!   👉 Read more: https://lnkd.in/eCm2wMUd   Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta, Lenka Michalkova #Biotech #Innovation #AccelerateInBasel #Therapeutics

If you have clinician colleagues who need CME or you are curious about DTx, check out our introductory course!

💡 HyBryte™: Advancing CTCL Care Soligenix (Nasdaq: SNGX) opens patient enrollment for its confirmatory trial of HyBryte™ for CTCL. ✅ Building on groundbreaking results to bring new hope to patients with limited options. 🔗 Read the full announcement: https://lnkd.in/esVpuvdH #CTCL #Biotech #BiotechNews #CancerResearch #FDA #FinancialNews #CapitalMarkets